Home > PORTAL > about Us > Presentation >
Learn how SPIN got started
SPIN – Skin Inflammation & Psoriasis International Network was initiated in 2004 as PIN – Psoriasis International Network by the FRT - Fondation René Touraine, a non-profit and a non-governmental organisation dedicated to support therapeutic progress in dermatology by fostering international collaborations.
After several European meetings on psoriasis held in Italy every 2 or 3 years, the FRT and Prof. Louis Dubertret organised the European Congress on Psoriasis - PSO 2004 in Paris, which acquired a great international dimension, with over 600 participants from 40 different countries. Following the PSO 2004 Congress, many participants showed great interest in developing networking activities in the field of psoriasis.
The founding meeting of the former PIN was held in Paris (Nov 18, 2005) between 20 countries willing to develop national psoriasis groups and willing to connect these groups into an international network. 11 countries were able to send a representative and 9 additional countries expressed a strong interest but were unable to come. The President of EUROPSO, the European federation of psoriasis associations, participated as well in the founding meeting.
This founding meeting formalised the international collaborations in the field of psoriasis started with the PSO 2004 Congress, creating thus the Psoriasis International Network. To develop this international network, it was proposed to:
• set up a website: www.psoriasis-international.org (now www.spindermatology.org!)
• organise every 3 years an International Congress on Psoriasis in Paris
• publish regular newsletters and "Focus On”
In 2011, a Scientific Committee was created to steer the scientific development of the network by proposing international collaborative projects, contributing to continuing medical training in psoriasis and supporting the development of national and regional psoriasis networks.
The network has grown ever since, gathering around 4700 healthcare professionals involved in the management of psoriasis from some 100 countries, 330 dermatology centres as well as 43 patient organisations. Since 2004, PIN has successfully:
• organised 5 international congresses on psoriasis and educational symposia during other dermatology meetings
• built a worldwide directory listing psoriasis medical resources for patients
• provided organisational support to the development of dedicated outpatient consultations at the local level
• fostered the development of national and regional networks on psoriasis
• carried out international studies on the current practice of the use of methotrexate and phototherapy in the treatment of psoriasis
• initiated a worldwide survey on the use of therapeutic patient education in psoriasis with the aim of developing a toolbox
• collaborated with the EADV Psoriasis Task Force since 2005.
In 2016, it was decided by the FRT Board of Directors to broaden the scope of the PIN to include other major chronic inflammatory skin diseases. This would allow to benefit from the benchmark of PIN’s actions and achievements in psoriasis and put it to the service of other diseases. With this change, we hope to transfer the know-how acquired on psoriasis (highest standard in issues such as quality of life, high burden and co-morbidities) and build on the collaborations made possible via the PIN network and expand them to other major chronic skin inflammatory diseases.
Following this decision, the former PIN Scientific Committee has decided to change the name of the network to SPIN – Skin Inflammation & Psoriasis International Network. On an operational level, the Committee decided to broaden the network’s scope progressively, one chronic inflammatory skin disease at a time. Starting in 2017, the new SPIN will cover psoriasis and expand its activities to atopic dermatitis.
SPIN Presentation
Recent news
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
- 2018/07/16 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
Aliment. Pharmacol. Ther..
2019 Aug , 50, (3):289-294.
Anti-TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases.
see on pubmed
Ginsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIIIγ expression in keratinocytes.
Biochem. Biophys. Res. Commun..
2019 Aug 06, 515, (4):665-671.
Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation. Ginsenoside compound K (CK), a bioactive metabolite of ginseng, modulates various skin disorders with an impact on keratinocyte biology. However, the effect of Ginsenoside CK in psoriasis has not been explored.
see on pubmed
A vivid cytokines interaction model on psoriasis with the effect of impulse biologic (TNF-α inhibitor) therapy.
J. Theor. Biol..
2019 Aug 07, 474:63-77.
Psoriasis is a chronic skin condition that produces plaques of condensed, scaling skin due to excessively rapid proliferation of keratinocytes. During the disease progression, keratinocyte proliferation is influenced by many immune cells and cytokines. This article deals with a five dimensional deterministic model, which has been derived using quasi-steady-state approximation for describing the dynamics of psoriasis in various cytokines environment. Equilibrium analysis of the system shows (...)
see on pubmed
on Atopic Dermatitis
Rhamnus prinoides (gesho): A source of diverse anti-biofilm activity.
Campbell M et al.
Rhamnus prinoides (gesho): A source of diverse anti-biofilm activity.
J Ethnopharmacol.
2019 Sep 15, 241:111955.
Rhamnus prinoides (gesho) is an evergreen shrub from East Africa traditionally used for the treatment of illnesses including atopic dermatitis, ear, nose and throat infections, pneumonia, arthritis, brucellosis, flu, indigestion and fatigue.
see on pubmed
Gardenia jasminoides extract without crocin improved atopic dermatitis-like skin lesions via suppression of Th2-related cytokines in Dfe-induced NC/Nga mice.
J Ethnopharmacol.
2019 Sep 15, 241:112015.
Atopic dermatitis (AD) is a pruritic, chronic, relapsing inflammatory skin disease. Gardenia jasminoides extract (GJE) has been used as a traditional remedy for the treatment of various inflammatory diseases, including AD. The specific effects of the extract components, which include crocin, geniposidic acid, and gardenoside, on inflammatory responses in AD are not entirely (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
